| scholarly article | Q13442814 |
| P50 | author | Michael Hennig | Q68093344 |
| P2093 | author name string | F Kullmann | |
| C Peschel | |||
| F Lordick | |||
| M Hentrich | |||
| J Duyster | |||
| S Lorenzen | |||
| U Vehling-Kaiser | |||
| R Bredenkamp | |||
| J Stollfuss | |||
| R Zumschlinge | |||
| H Dietzfelbinger | |||
| T Seroneit | |||
| J Thoedtmann | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial | Q33337143 | ||
| Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study | Q33341477 | ||
| Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients | Q33345474 | ||
| Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer | Q33359580 | ||
| Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. | Q33361500 | ||
| Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study | Q33362191 | ||
| Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer | Q33810043 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 | ||
| Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate | Q41231593 | ||
| Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial | Q42285544 | ||
| Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer | Q44028630 | ||
| Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. | Q44057365 | ||
| Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer | Q44547446 | ||
| Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma | Q44695858 | ||
| Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients | Q44785275 | ||
| Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. | Q44919656 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the | Q74000577 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oxaliplatin | Q422327 |
| fluorouracil | Q238512 | ||
| P304 | page(s) | 190-194 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer | |
| P478 | volume | 93 |
| Q36609591 | A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer |
| Q36614036 | A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer |
| Q87442293 | A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases |
| Q54645262 | A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer. |
| Q38844897 | CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers |
| Q33658636 | Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). |
| Q34617795 | Chemotherapy for advanced gastric cancer: across the years for a standard of care |
| Q36610915 | Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. |
| Q33399154 | Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer |
| Q35948108 | Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer |
| Q36616503 | Docetaxel in the treatment of gastric cancer |
| Q36615632 | ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen |
| Q35340883 | Efficacy and safety of oxaliplatin, 5-Fluorouracil, and folinic Acid combination chemotherapy as first-line treatment in metastatic or recurrent gastric cancer |
| Q61868148 | Is oxaliplatin the optimal platinum agent in gastric cancer? |
| Q33337970 | Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker |
| Q36450765 | Multimodality treatment of esophageal cancer: a review of the current status and future directions |
| Q45306704 | Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer |
| Q36936039 | Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial |
| Q38139297 | Optimal chemotherapy for advanced gastric cancer: is there a global consensus? |
| Q37336375 | Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer |
| Q36610215 | Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study |
| Q34670947 | Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer |
| Q33728364 | Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients |
| Q33383287 | Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study |
| Q33378971 | Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin |
| Q37134006 | Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma |
| Q42986070 | Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer |
| Q42181610 | Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials |
| Q36376439 | Recent developments in the systemic therapy of advanced gastroesophageal malignancies |
| Q35076251 | Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. |
| Q41762961 | The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy |
| Q33405235 | The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial |
| Q34214957 | Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers |
| Q41610787 | Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case |
| Q38565576 | Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer |
| Q33242985 | Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial |
| Q28246258 | mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer |
Search more.